S&P 500   4,396.28 (+1.07%)
DOW   34,620.50 (+1.32%)
QQQ   348.14 (+1.04%)
AAPL   162.96 (+2.05%)
MSFT   305.53 (+2.97%)
FB   300.31 (+1.93%)
GOOGL   2,638.40 (+2.08%)
AMZN   2,862.97 (+3.08%)
TSLA   873.36 (-6.83%)
NVDA   224.55 (-1.39%)
BABA   113.74 (+0.33%)
NIO   21.85 (-3.57%)
AMD   105.89 (-4.35%)
CGC   7.01 (-3.04%)
MU   81.14 (-1.01%)
GE   90.40 (+1.21%)
T   24.37 (+0.49%)
F   19.94 (+0.15%)
DIS   137.77 (+3.12%)
AMC   15.03 (-5.71%)
PFE   54.50 (+2.81%)
ACB   3.92 (-3.45%)
BA   194.36 (+0.05%)
S&P 500   4,396.28 (+1.07%)
DOW   34,620.50 (+1.32%)
QQQ   348.14 (+1.04%)
AAPL   162.96 (+2.05%)
MSFT   305.53 (+2.97%)
FB   300.31 (+1.93%)
GOOGL   2,638.40 (+2.08%)
AMZN   2,862.97 (+3.08%)
TSLA   873.36 (-6.83%)
NVDA   224.55 (-1.39%)
BABA   113.74 (+0.33%)
NIO   21.85 (-3.57%)
AMD   105.89 (-4.35%)
CGC   7.01 (-3.04%)
MU   81.14 (-1.01%)
GE   90.40 (+1.21%)
T   24.37 (+0.49%)
F   19.94 (+0.15%)
DIS   137.77 (+3.12%)
AMC   15.03 (-5.71%)
PFE   54.50 (+2.81%)
ACB   3.92 (-3.45%)
BA   194.36 (+0.05%)
S&P 500   4,396.28 (+1.07%)
DOW   34,620.50 (+1.32%)
QQQ   348.14 (+1.04%)
AAPL   162.96 (+2.05%)
MSFT   305.53 (+2.97%)
FB   300.31 (+1.93%)
GOOGL   2,638.40 (+2.08%)
AMZN   2,862.97 (+3.08%)
TSLA   873.36 (-6.83%)
NVDA   224.55 (-1.39%)
BABA   113.74 (+0.33%)
NIO   21.85 (-3.57%)
AMD   105.89 (-4.35%)
CGC   7.01 (-3.04%)
MU   81.14 (-1.01%)
GE   90.40 (+1.21%)
T   24.37 (+0.49%)
F   19.94 (+0.15%)
DIS   137.77 (+3.12%)
AMC   15.03 (-5.71%)
PFE   54.50 (+2.81%)
ACB   3.92 (-3.45%)
BA   194.36 (+0.05%)
S&P 500   4,396.28 (+1.07%)
DOW   34,620.50 (+1.32%)
QQQ   348.14 (+1.04%)
AAPL   162.96 (+2.05%)
MSFT   305.53 (+2.97%)
FB   300.31 (+1.93%)
GOOGL   2,638.40 (+2.08%)
AMZN   2,862.97 (+3.08%)
TSLA   873.36 (-6.83%)
NVDA   224.55 (-1.39%)
BABA   113.74 (+0.33%)
NIO   21.85 (-3.57%)
AMD   105.89 (-4.35%)
CGC   7.01 (-3.04%)
MU   81.14 (-1.01%)
GE   90.40 (+1.21%)
T   24.37 (+0.49%)
F   19.94 (+0.15%)
DIS   137.77 (+3.12%)
AMC   15.03 (-5.71%)
PFE   54.50 (+2.81%)
ACB   3.92 (-3.45%)
BA   194.36 (+0.05%)

HealthEquity, Inc. (NASDAQ:HQY) Short Interest Up 22.3% in December

Saturday, January 8, 2022 | MarketBeat

HealthEquity, Inc. (NASDAQ:HQY) saw a large increase in short interest in the month of December. As of December 15th, there was short interest totalling 3,730,000 shares, an increase of 22.3% from the November 30th total of 3,050,000 shares. Based on an average trading volume of 743,300 shares, the short-interest ratio is currently 5.0 days. Approximately 4.6% of the shares of the stock are sold short.

Shares of NASDAQ HQY traded down $0.89 during trading on Friday, hitting $45.40. 657,836 shares of the company traded hands, compared to its average volume of 771,207. HealthEquity has a 1 year low of $36.81 and a 1 year high of $93.32. The company has a 50-day moving average price of $54.30 and a 200-day moving average price of $64.40. The firm has a market capitalization of $3.80 billion, a P/E ratio of -654.76, a P/E/G ratio of 3.24 and a beta of 1.21. The company has a quick ratio of 7.14, a current ratio of 7.14 and a debt-to-equity ratio of 0.49.

HealthEquity (NASDAQ:HQY) last announced its quarterly earnings data on Monday, December 6th. The company reported $0.35 earnings per share (EPS) for the quarter, meeting the Thomson Reuters' consensus estimate of $0.35. HealthEquity had a negative net margin of 0.82% and a positive return on equity of 4.60%. The company had revenue of $180.00 million during the quarter, compared to analysts' expectations of $185.44 million. During the same period in the previous year, the company earned $0.30 EPS. The business's quarterly revenue was up .3% compared to the same quarter last year. Research analysts predict that HealthEquity will post 0.83 EPS for the current fiscal year.

In related news, Director Stuart B. Parker purchased 25,000 shares of HealthEquity stock in a transaction dated Thursday, December 9th. The stock was bought at an average cost of $42.82 per share, for a total transaction of $1,070,500.00. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. Also, VP William Robert Otten sold 1,850 shares of HealthEquity stock in a transaction that occurred on Monday, November 1st. The shares were sold at an average price of $66.42, for a total transaction of $122,877.00. The disclosure for this sale can be found here. 2.80% of the stock is currently owned by company insiders.

Several hedge funds and other institutional investors have recently made changes to their positions in HQY. Advisor Group Holdings Inc. lifted its holdings in shares of HealthEquity by 29.4% during the 2nd quarter. Advisor Group Holdings Inc. now owns 5,559 shares of the company's stock valued at $447,000 after acquiring an additional 1,263 shares in the last quarter. Envestnet Asset Management Inc. lifted its holdings in shares of HealthEquity by 35.6% during the 2nd quarter. Envestnet Asset Management Inc. now owns 39,989 shares of the company's stock valued at $3,218,000 after acquiring an additional 10,504 shares in the last quarter. Teacher Retirement System of Texas lifted its holdings in shares of HealthEquity by 17.5% during the 2nd quarter. Teacher Retirement System of Texas now owns 10,116 shares of the company's stock valued at $814,000 after acquiring an additional 1,504 shares in the last quarter. Swiss National Bank lifted its holdings in shares of HealthEquity by 3.1% during the 2nd quarter. Swiss National Bank now owns 181,100 shares of the company's stock valued at $14,575,000 after acquiring an additional 5,500 shares in the last quarter. Finally, HighTower Advisors LLC lifted its holdings in shares of HealthEquity by 0.7% during the 2nd quarter. HighTower Advisors LLC now owns 83,940 shares of the company's stock valued at $6,758,000 after acquiring an additional 543 shares in the last quarter. 99.48% of the stock is owned by institutional investors.

A number of brokerages have recently weighed in on HQY. TheStreet cut shares of HealthEquity from a "c" rating to a "d+" rating in a research note on Tuesday, December 7th. Royal Bank of Canada dropped their price objective on shares of HealthEquity from $87.00 to $70.00 and set an "outperform" rating for the company in a research note on Tuesday, December 7th. JPMorgan Chase & Co. dropped their price objective on shares of HealthEquity from $82.00 to $56.00 and set an "overweight" rating for the company in a research note on Tuesday, December 21st. Deutsche Bank Aktiengesellschaft dropped their price objective on shares of HealthEquity from $75.00 to $52.00 and set a "buy" rating for the company in a research note on Wednesday, December 8th. Finally, Raymond James cut shares of HealthEquity from a "strong-buy" rating to an "outperform" rating and dropped their price objective for the stock from $90.00 to $70.00 in a research note on Tuesday, December 7th. Two research analysts have rated the stock with a hold rating and nine have assigned a buy rating to the stock. Based on data from MarketBeat, the company has an average rating of "Buy" and a consensus target price of $74.00.

HealthEquity Company Profile

HealthEquity, Inc provides range of solutions for managing health care accounts. The firm's offers its solutions for employers, health plans, brokers, consultants and financial advisors. Its services include HAS, FSA, HRA, DCRA, 401(k), Commuter, COBRA and HIA. It also offers products like healthcare saving and spending platform, health savings accounts, investment advisory services, reimbursement arrangements, and healthcare incentives.

Featured Story: Capital Gains

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to [email protected]

Should you invest $1,000 in HealthEquity right now?

Before you consider HealthEquity, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and HealthEquity wasn't on the list.

While HealthEquity currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.

View The 5 Stocks Here

 


Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.